Drug Development and Generics: What Sandoz CEO Thinks About Pharmaceuticals in the 2024 Elections
Tuesday, 15 October 2024, 01:32
Drug development and generics are key issues as Sandoz CEO Richard Saynor weighs in on the upcoming 2024 elections. In his recent commentary, he criticizes the tendency to blame 'Big Pharma' while neglecting the vital support needed for the market for generic and biosimilar medicines. This perspective invites a deeper look into the challenges and opportunities facing the pharmaceuticals sector as we head into the elections.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.